📊 VIVS Key Takeaways
Is VivoSim Labs, INC. (VIVS) a Good Investment?
VivoSim Labs exhibits critical financial distress with a non-viable operating model: $8.3M operating losses on only $91K in revenue represents a fundamental breakdown in business economics. Current cash burn of $8.6M annually depletes the $4.3M cash position within months, creating imminent solvency risk without significant capital raises or dramatic revenue acceleration.
Why Buy VivoSim Labs, INC. Stock? VIVS Key Strengths
- No debt burden provides flexibility for capital structure
- Adequate short-term liquidity with 2.44x current ratio
- Revenue growing 32.1% YoY indicates emerging sales traction
VIVS Stock Risks: VivoSim Labs, INC. Investment Risks
- Operating loss of $8.3M on $91K revenue is unsustainable and indicates business model failure
- Cash runway of ~6 months at current burn rate with imminent depletion risk
- Operating margin of -9121% and ROA of -116% show severe capital inefficiency
- Pre-commercial stage with zero path to near-term profitability
- Stockholder equity at risk of substantial dilution through future capital raises
Key Metrics to Watch
- Operating cash flow trajectory and monthly burn rate
- Revenue growth rate - must exceed burn rate for viability
- Cash position relative to runway - any depletion below 3 months is critical
- Insider transaction activity - concentration/timing of Form 4s may signal confidence or concern
VivoSim Labs, INC. (VIVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.44x current ratio provides a solid financial cushion.
VIVS Profit Margin, ROE & Profitability Analysis
VIVS vs Healthcare Sector: How VivoSim Labs, INC. Compares
How VivoSim Labs, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is VivoSim Labs, INC. Stock Overvalued? VIVS Valuation Analysis 2026
Based on fundamental analysis, VivoSim Labs, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
VivoSim Labs, INC. Balance Sheet: VIVS Debt, Cash & Liquidity
VIVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: VivoSim Labs, INC.'s revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-19.25 indicates the company is currently unprofitable.
VIVS Revenue Growth, EPS Growth & YoY Performance
VIVS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.0K | -$2.7M | $-0.19 |
| Q2 2025 | N/A | -$2.5M | $-0.14 |
| Q1 2025 | $37.0K | -$2.8M | $-0.23 |
| Q3 2023 | N/A | -$3.3M | $-0.37 |
| Q2 2023 | N/A | -$3.3M | $-0.38 |
| Q1 2023 | N/A | -$2.5M | $-0.29 |
| Q3 2021 | N/A | -$2.5M | N/A |
| Q2 2021 | N/A | -$6.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
VivoSim Labs, INC. Dividends, Buybacks & Capital Allocation
VIVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for VivoSim Labs, INC. (CIK: 0001497253)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VIVS
What is the AI rating for VIVS?
VivoSim Labs, INC. (VIVS) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VIVS's key strengths?
Claude: No debt burden provides flexibility for capital structure. Adequate short-term liquidity with 2.44x current ratio.
What are the risks of investing in VIVS?
Claude: Operating loss of $8.3M on $91K revenue is unsustainable and indicates business model failure. Cash runway of ~6 months at current burn rate with imminent depletion risk.
What is VIVS's revenue and growth?
VivoSim Labs, INC. reported revenue of $91.0K.
Does VIVS pay dividends?
VivoSim Labs, INC. does not currently pay dividends.
Where can I find VIVS SEC filings?
Official SEC filings for VivoSim Labs, INC. (CIK: 0001497253) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VIVS's EPS?
VivoSim Labs, INC. has a diluted EPS of $-3.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VIVS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, VivoSim Labs, INC. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VIVS stock overvalued or undervalued?
Valuation metrics for VIVS: ROE of -181.9% (sector avg: 15%), net margin of -8,878.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VIVS stock in 2026?
Our dual AI analysis gives VivoSim Labs, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VIVS's free cash flow?
VivoSim Labs, INC.'s operating cash flow is $-8.6M, with capital expenditures of $0.0. FCF margin is -9,438.5%.
How does VIVS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8,878.0% (avg: 12%), ROE -181.9% (avg: 15%), current ratio 2.44 (avg: 2).